Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study Combining Trastuzumab With Etoposide in Treatment of HER2-Positive Metastatic Breast Cancer.

NCT00810017 is registered in ClinicalTrials.gov with Medstar Health Research Institute as lead sponsor.

NCT NCT00810017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00810017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study Combining Trastuzumab With Etoposide in Treatment of HER2-Positive Metastatic Breast Cancer.
Lead sponsor
Medstar Health Research Institute
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2009
Completion date
June 30, 2010
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive metastatic breast cancer